摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[4-(2-甲基苯基)哌嗪-1-基]乙酮 | 101975-77-3

中文名称
1-[4-(2-甲基苯基)哌嗪-1-基]乙酮
中文别名
——
英文名称
1-acetyl-4-o-tolyl-piperazine
英文别名
1-Acetyl-4-o-tolyl-piperazin;Piperazine, 1-acetyl-4-o-tolyl-;1-[4-(2-methylphenyl)piperazin-1-yl]ethanone
1-[4-(2-甲基苯基)哌嗪-1-基]乙酮化学式
CAS
101975-77-3
化学式
C13H18N2O
mdl
MFCD00861881
分子量
218.299
InChiKey
JBTQRFMTDYRGLH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.461
  • 拓扑面积:
    23.6
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PRMT5 CONTENANT UNE DIHYDRO- OU TÉTRAHYDRO-ISOQUINOLÉINE ET LEURS UTILISATIONS
    申请人:EPIZYME INC
    公开号:WO2014100730A1
    公开(公告)日:2014-06-26
    Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.
    本文描述了式(A)的化合物,其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
  • [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
    申请人:EPIZYME INC
    公开号:WO2014100734A1
    公开(公告)日:2014-06-26
    Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
    本文描述了式(A)的化合物,其药学上可接受的盐以及药物组成物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
  • AZOLECARBOXAMIDE DERIVATIVE
    申请人:Sugasawa Keizo
    公开号:US20090286766A1
    公开(公告)日:2009-11-19
    Provided is an agent for treating or preventing urinary frequency, urinary urgency and urinary, incontinence which are associated with overactive bladder, a lower urinary tract disease such as interstitial cystitis and chronic prostatitis accompanied by lower urinary tract pain, and various diseases accompanied by pain. A novel azolecarboxamide derivative in which an azole ring such as thioazole or oxazole is bonded to a benzene ring, pyridine ring or pyrimidine ring through carboxamide was confirmed to have a potent trkA receptor-inhibitory activity and found to be an agent for treating or preventing lower urinary tract disease and various diseases accompanied by pain, which is excellent in efficacy and safety, and thus the present invention was accomplished.
    提供了一种用于治疗或预防与过度活跃膀胱、下泌尿道疾病(如间质性膀胱炎和慢性前列腺炎伴随下泌尿道疼痛)以及伴随疼痛的各种疾病相关的尿频、尿急和尿失禁的药剂。一种新型的唑烷羧酰胺衍生物,其中唑环(如硫唑环或噁唑环)通过羧酰胺键连接到苯环、吡啶环或嘧啶环上,被证实具有强效的trkA受体抑制活性,并被发现是一种用于治疗或预防下泌尿道疾病和伴随疼痛的各种疾病的药剂,其疗效和安全性优异,因此本发明得以完成。
  • PRMT5 INHIBITORS AND USES THEREOF
    申请人:Epizyme, Inc.
    公开号:US20150191432A1
    公开(公告)日:2015-07-09
    Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
    本文描述了公式(I)的化合物,其药学上可接受的盐和制药组合物。本发明的化合物对于抑制PRMT5活性是有用的。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
  • TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF
    申请人:EPIZYME, INC.
    公开号:US20150344434A1
    公开(公告)日:2015-12-03
    Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described.
    本文描述了公式(A)的化合物,其药学上可接受的盐以及它们的药物组合物。本发明的化合物对于抑制PRMT5活性是有用的。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
查看更多